Figure S7.

Quantitation of B Cells, Related to Figures 5 and 6

Quantitation of absolute B cell counts was undertaken in all COVID-19 patients in whom a proximal absolute lymphocyte count (ALC) was available in the electronic medical record at states of convalescence (n = 5), severe illness with an intermediate maximum CRP level during hospitalization (< 200 mg/L; severe (CRP int); n = 10), and severe illness with a high maximum CRP level during hospitalization (> 200 mg/L; severe (CRP hi); n = 15) as defined by the clinical criteria listed in Table S4. Data are compared to healthy controls (n = 4), assuming a healthy control ALC of 2.9 (K/uL). Quantitation shown by B cell level for each individual patient with mean, standard deviation, and significance by one-way ANOVA of log % B cell value indicated (^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001) for (A) total CD19⁺ B cells, (B) naive, early transitional (T1/2), and follicular (FO) B cell subsets, (C) activated and double negative (DN) B cell subsets as indicated, and (D) activated and DN B cell subsets as a ratio to the available precursor population (naive, IgD⁺CD27^-).